The global Progressive Pulmonary Fibrosis (PPF) Treatment Market is set to achieve a valuation of USD 3.72 million in 2023, ...

Patients with COPD and type 2 diabetes using SGLT2i were much less likely to have ER visits and hospitalizations related to COPD exacerbations.

Chronic obstructive pulmonary disease is a serious, progressive illness that hits the homeless and underinsured the hardest.

Chronic Pulmonary Hypertension Treatment Market. The global chronic pulmonary hypertension treatment market is expected to ...

糖皮质激素（GC）的药理作用及临床适应症广泛，因其强大的抗炎、平喘作用，在呼吸科常被用于 慢性阻塞性肺疾病 （ COPD ）、 哮喘 等疾病治疗。GC 可缓解患者的临床症状、改善肺功能，提高生活质量。

Discover the latest insights from the TOReTO study on COPD management: Dual bronchodilator therapy has been shown to reduce exacerbations, with varying efficacy between current and former smokers.

As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up ...

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

New funding from Biocurate will support a Monash University project that's developing a novel disease-modifying treatment for ...

The trial adds much-needed randomized data to an area where it’s been lacking. Questions about methods muddy interpretation.

The effort by the Center for Regenerative Medicine of Boston University, Boston Medical Center, and GSK aims to find new ...

Findings from the first international randomized controlled trial to compare patient outcomes following treatment with ...